BMO Capital Downgrades Stealth BioTherapeutics (MITO) to Market Perform
Tweet
Share
E-mailGet Alerts MITO Hot Sheet
Price: $0.32 --0%
Rating Summary:
5 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
5 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
BMO Capital analyst Matthew Luchini downgraded Stealth BioTherapeutics (NASDAQ: MITO) from Outperform to Market Perform with a price target of $7.00 (from $28.00).
For an analyst ratings summary and ratings history on Stealth BioTherapeutics click here. For more ratings news on Stealth BioTherapeutics click here.
Shares of Stealth BioTherapeutics closed at $13.70 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Downgrades Limbach Holdings (LMB) to Underweight
- BMO Capital Starts Semtech Corp. (SMTC) at Outperform
- Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
Create E-mail Alert Related Categories
DowngradesRelated Entities
BMO CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
